NMR vs SOFI

Nomura Holdings presents a stark contrast between attractive valuation and poor operational health, highlighted by a weak Piotroski F-Score of 2/9. While the stock trades significantly below its Graham Number ($11.50) and Intrinsic Value ($10.31), the fundamental health metrics are concerning. Strong revenue growth and a healthy dividend yield are offset by extreme leverage (Debt/Equity of 9.17) and a consistent track record of missing earnings estimates. The current price of $8.06 suggests a value play, but the lack of operational momentum warrants a neutral stance.

SOFI exhibits severe fundamental weakness as evidenced by a Piotroski F-Score of 2/9, indicating poor operational health. The stock is trading at a significant premium to both its Graham Number ($8.51) and Intrinsic Value ($2.73), suggesting a valuation disconnected from current financial realities. While revenue growth remains robust at 40.20%, the sharp decline in YoY earnings growth (-57%) and bearish insider activity signal internal instability. The combination of a weak deterministic health score and a bearish technical trend outweighs the positive analyst target prices.